Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Roche
Nearly 60 New Studies of Oral Xeloda capecitabine Featured at the 44th American Society of Clinical Oncology Annual Meeting
June 3rd, 2008
Roche announced that a total of 59 U.S. and global abstracts involving its oral chemotherapy Xeloda(R) (capecitabine) have been accepted for presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. A U.S. abstract to be published in The 2008 ASCO Proceedings I, compares the preclinical efficacy of an investigational, seven-days-on/seven-days-off (7-on/7-off) Xeloda regimen versus the current standard Xeloda dosing of fourteen-days-on/seven-days-off (14-on/7-off) in colorectal cancer. Findings from this study appeared to indicate improved tumor growth inhibition with the 7-on/7-off Xeloda regimen; results...
Source: Cancer Weekly (2008-06-03)
|
